Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
This clinical trial is designed to prove the efficacy and safety of Fexinidazole as an oral treatment for human african trypanosomiasis in advanced stage. The Fexinidazole is compared to reference treatment NECT. The trial will try to demonstrate that Fexinidazole is not inferior to NECT treatment.
Human African Trypanosomiasis
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study|
- success or failure at 18 months FU visit [ Time Frame: 18 months after treatment ] [ Designated as safety issue: No ]
The primary endpoint is the outcome (success or failure) at the test of cure (ToC) visit 18 months after the end of treatment (EOT) adapted from WHO criteria.
Success at 18 months is:
- patient alive,
- AND with no evidence of trypanosomes in any body fluid,
- AND 20 or less WBC/µl CSF
Or Probable cure:
- Patient with no parasitological evidence of relapse in blood and lymph
- AND who refuses lumbar puncture OR whose CSF sample is haemorrhagic without trypanosomes
- AND whose clinical condition is satisfactory (without clinical symptom or signs) OR whose clinical status is unlikely to be due to HAT
- Safety endpoint [ Time Frame: 18 days - observation period ] [ Designated as safety issue: Yes ]
Occurrence of any grade (all grades combined) adverse events during the observation period (D1-18) including:
- any worsening of clinical symptoms listed in the inclusion checklist of symptoms and signs,
- laboratory abnormalities of grade ≥ 2
- Occurrence of grade ≥ 3 adverse events during the observation period
- Occurrence of drug-related adverse events (grade ≥ 3 and any grade) during the observation period
- Safety endpoint [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]Occurrence of any serious adverse events from first drug intake to the end of follow-up period (18 months), and from M18 to M24.
- Pharmacokinetics endpoint [ Time Frame: from D8 to D12 after first dosing ] [ Designated as safety issue: No ]Whole blood and CSF concentrations of fexinidazole, M1, M2 and PK parameters derived from a model of population PK data.
- QT evaluation [ Time Frame: D0 - D4 - D10 ] [ Designated as safety issue: Yes ]recording of triplicates ECG
|Study Start Date:||October 2012|
|Estimated Study Completion Date:||September 2016|
|Estimated Primary Completion Date:||March 2016 (Final data collection date for primary outcome measure)|
Active Comparator: NECT (Nifurtimox Eflornithine Combination Therapy)
Other Name: LampitDrug: Eflornithine
Other Name: Ornidyl
Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:
Human African Trypanosomiasis (HAT) is a life-threatening and neglected disease.
Few treatment options are currently available for stage 2 (meningo-encephalitic stage) HAT, with NECT being the most commonly used one since 2010. Though NECT represents a significant improvement over current therapies, it is still far from ideal given the environment in which HAT patients live (remote, poor areas with little health infrastructure, if any, and difficult logistics). There is an urgent need for less toxic and more easily manageable compounds to treat this fatal disease.
Fexinidazole is a 2-5-nitroimidazole, formulated for oral administration, which has been shown to possess in vitro and in vivo activity against both T. b. rhodesiense and T. b. gambiense parasites.
Predicted CSF concentrations reached target levels after repeated dosing. Its efficacy and safety must now be tested in patients with stage 2 HAT.
|Contact: Antoine Tarral, MDemail@example.com|
|Contact: Séverine Blesson, Mscfirstname.lastname@example.org|
|Central African Republic|
|Batangafo||Not yet recruiting|
|Batangafo, Central African Republic|
|Principal Investigator: Francis Regongbenga, MD|
|Masi Manimba Hospital||Not yet recruiting|
|Masi Manimba, Bandundu - DRC, Congo|
|Contact: Willy Kuziena, MD|
|Principal Investigator: Willy Kuziena, MD|
|Vanga, Bandundu - DRC, Congo|
|Principal Investigator: Jean-Pierre Fina, MD|
|CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital||Not yet recruiting|
|Mbuji Mayi, East Kasai, Congo|
|Contact: , MD|
|Principal Investigator: Médard Ilunga, MD|
|HGR (General Reference Hospital) Bandundu||Recruiting|
|Principal Investigator: Pathou Nganzobo, MD|
|Dingila||Not yet recruiting|
|Principal Investigator: Josué Amici, MD|
|Principal Investigator:||Victor KANDE, MD||HAT National Control Program in DRC|